Agent’s Information. As used in this Agreement, “Agent’s Information” means solely the following information in the Registration Statement and the Prospectus: the eighth paragraph under the heading “Plan of Distribution” in the Prospectus Supplement. All references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to XXXXX. All references in this Agreement to financial statements and schedules and other information that is “contained,” “included” or “stated” in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement or the Prospectus, as the case may be. All references in this Agreement to “supplements” to the Prospectus shall include any supplements, “wrappers” or similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States. If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agent. Very truly yours, Tenaya Therapeutics, Inc. By: /s/ Leone X. Xxxxxxxxx, M.B.A. Name: Leone X. Xxxxxxxxx, M.B.A. Title: Chief Financial and Business Officer By: /s/ Xxxxx X. Xxx Name: Xxxxx X. Xxx Title: Head of Alternative Equities From: [ ] [TITLE] Tenaya Therapeutics, Inc. Cc: [ ] To: SVB Securities LLC Subject: SVB Securities—At the Market Offering—Placement Notice Ladies and Gentlemen: Pursuant to the terms and subject to the conditions contained in the Sales Agreement, dated August 10, 2022 (the “Agreement”), by and between Tenaya Therapeutics, Inc., a Delaware corporation (the “Company”), and SVB Securities LLC (“SVB Securities”), I hereby request on behalf of the Company that SVB Securities sell up to [ ] shares of common stock, $0.0001 par value per share, of the Company (the “Shares”), at a minimum market price of $ per share[; provided that no more than [ ] Shares shall be sold in any one Trading Day (as such term is defined in Section 3 of the Agreement)]. Sales should begin [on the date of this Placement Notice] and end on [DATE] [until all Shares that are the subject of this Pl...
Agent’s Information. As used in this Agreement, “Agent’s Information” means solely the following information in the Registration Statement and the Prospectus: the first and last sentences of the eighth paragraph and the full tenth paragraph under the heading “Plan of Distribution” in the Prospectus. All references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to EXXXX. All references in this Agreement to financial statements and schedules and other information that is “contained,” “included” or “stated” in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement or the Prospectus, as the case may be. All references in this Agreement to “supplements” to the Prospectus shall include any supplements, “wrappers” or similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States. If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agent. Very truly yours, AEON BIOPHARMA, INC. By: /s/ Mxxx Xxxxx Name: Mxxx Xxxxx Title: President and Chief Executive Officer ACCEPTED as of the date first-above written: LEERINK PARTNERS LLC By: /s/ Pxxxx X. Xxx Name: Pxxxx X. Xxx Title: Head of Alternative Equities From: [ ] [TITLE] [AEON Biopharma, Inc.] Cc: [ ] To: Leerink Partners LLC Subject: Leerink Partners —At the Market Offering—Placement Notice Ladies and Gentlemen: Pursuant to the terms and subject to the conditions contained in the Sales Agreement, dated [●], 2024 (the “Agreement”), by and between AEON Biopharma, Inc., a Delaware corporation (the “Company”), and Leerink Partners LLC (“Leerink Partners”), I hereby request on behalf of the Company that Leerink Partners sell up to [ ] shares of Class A common stock, $0.0001 par value per share, of the Company (the “Shares”), at a minimum market price of $ per share[; provided that no more than [ ] Shares shall be sold in any one Trading Day (as such term is defined in Section 3 of the Agreement)]. Sales should begin [on the date of this ...
Agent’s Information. As used in this Agreement, “Agent’s Information” means solely the following information in the Registration Statement and the Prospectus: the last sentence of the eighth paragraph and the ninth paragraph under the heading “Plan of Distribution” in the Prospectus Supplement.
Agent’s Information. As used in this Agreement, “Agent’s Information” means, solely the following information in the Prospectus: the fifth paragraph under the caption “Plan of Distribution” in the ATM Prospectus. All references in this Agreement to financial statements and schedules and other information that is “contained,” “included” or “stated” in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement or the Prospectus, as the case may be. All references in this Agreement to “supplements” to the Prospectus shall include, without limitation, any supplements, “wrappers” or similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by HCW outside of the United States. If the foregoing correctly sets forth the understanding between the Company and HCW, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and HCW. Very truly yours, By: /s/ Xxxx X. Viklund Name: Xxxx X. Viklund Title: Chief Executive Officer By: /s/ Xxxxx Xxxxxxx Name: Xxxxx Xxxxxxx Title: President and Chief Executive Officer From: [ ] Cc: [ ] To: [ ] Subject: HCW at the Market Offering—Placement Notice Ladies and Gentlemen: Pursuant to the terms and subject to the conditions contained in the Sales Agreement between Proteostasis Therapeutics, Inc. (the “Company”), and X.X. Xxxxxxxxxx & Co., LLC (“HCW”) dated [ ], 2019 (the “Agreement”), I hereby request on behalf of the Company that HCW sell up to [ ] shares of the Company’s common stock, par value $0.001 per share [(“Common Stock”)], at a minimum market price of $ per share[, provided that no more than [ ] shares of Common Stock shall be sold in any one Trading Day, as such term is defined in Section 3 of the Agreement]. Sales should begin on the date of this Notice and shall continue until [DATE] [all shares are sold]. Xxxxx Xxxxxxx Xxxxx Xxxxx Xxxxx Xxx xxxx@xxxxx.xxx Xxxxxxx Xxxxxxxx xxxxxxxxxx@xxxxx.xxx With a copy to xxx@xxxxx.xxx HCW shall be paid compensation equal to 3% of the gross proceeds from the sales of Common Stock pursuant to the terms of this Agreement. The undersigned, the duly qualified and elected [ ], of Proteostasis Therapeutics, Inc. (“Company”), a Delaware corporation, does hereby certify in such capacit...
Agent’s Information. The parties hereto acknowledge and agree that, for all purposes of this Agreement, the “Agent’s Information” consists solely of the following information in the Prospectus Supplement: (i) the third paragraph on the front cover page concerning the terms of the offering; and (ii) the statements concerning the Agent contained in the first paragraph, concerning the Agent in the third paragraph, concerning the Agent and Lazard Frères & Co. LLC in the eighth paragraph and concerning Regulation M of the Exchange Act in the eleventh paragraph, in each case under the heading “Plan of Distribution.”
Agent’s Information. (1) The Customer authorizes the Bank to retain an affiliated company and/or any other agents to perform data processing, collection and other services with respect to any Account which the Bank considers necessary or desirable for the Bank. The Bank reserves the right to modify or terminate the Bank’s arrangements with the Bank’s agents at any time.
(2) The Customer agrees that requests, instructions, and information with respect to the Account, the Customer itself, and transactions relating to the Account or Customer, and any information disclosed in accordance with this Agreement and any other Account documentation (collectively, “Account Data”), may be processed, collected and transmitted for any legitimate purpose. The Customer specifically understands and agrees that Account Data may be transmitted across national boundaries and through networks, including networks owned and operated by third parties. The Customer explicitly authorizes the Bank to disclose Account Data (including any confidential information as may be protected under U.S. Federal or State law, or any law of the Federal Republic of Germany, any law of the European Union, or as defined in the “Confidential Relationships (Preservation) Law” of the Cayman Islands) for any legitimate purpose, including without limitation, under any of the following circumstances: (a) the disclosure, in the Bank’s opinion, is necessary or desirable for the purpose of allowing the Bank to perform its duties and to exercise its powers and rights hereunder or under any other Account documentation; (b) the disclosure is to a proposed assignee of the rights of the Bank; (c) the disclosure is to a branch, affiliate, subsidiary, employee or agent of the Bank or to its or their respective auditors, regulators or legal advisers;(d) the disclosure is to the auditors of the Customer; or (e) the disclosure is permitted or required by law or regulation (including any law of the Federal Republic of Germany or the European Union ), regardless of whether the disclosure is made in the country in which the Customer resides, in which the Account is maintained, or in which the transaction is conducted.
Agent’s Information. As used in this Agreement, “Agents’ Information” means solely the following information in the Registration Statement and the Prospectus: the tenth and eleventh paragraphs under the heading “Plan of Distribution” in the Prospectus Supplement.
Agent’s Information. As used in this Agreement, “Agent’s Information” means solely the following information in the Registration Statement and the Prospectus: the last sentence of the eighth paragraph and the tenth paragraph under the heading “Plan of Distribution” in the Sales Agreement Prospectus. All references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to XXXXX. All references in this Agreement to financial statements and schedules and other information that is “contained,” “included” or “stated” in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement or the Prospectus, as the case may be.
Agent’s Information. The agent is required to provide: - Copy of Agent Business’ Registration - Copy of the Business Owner’s pictured I.D. - Business Void Cheque - Personal Void Cheque
